Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MK-4830 by Merck for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
MK-4830 is under clinical development by Merck and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According to...
Risk adjusted net present value: What is the current valuation of Merck's MK-4830?
MK-4830 is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Non-Small Cell Lung Cancer. According...
Risk adjusted net present value: What is the current valuation of Merck's MK-4830?
MK-4830 is a monoclonal antibody commercialized by Merck, with a leading Phase II program in Esophageal Squamous Cell Carcinoma (ESCC)....